Plain-English translation of NCT07233642 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new type of treatment called ultra-fast autologous CD19-targeted CAR-T therapy for people whose lupus has not improved with standard medications. The treatment works by taking some of your own immune cells, genetically modifying them in the laboratory to target and eliminate cells driving your lupus, and then returning them to your body. This approach is very new and shows promise for potentially offering a more lasting improvement than current treatments.
Current lupus treatments rely on medicines that control symptoms but don't cure the disease, meaning most patients must take medication for life and often experience flare-ups when stopping treatment. This new medication offers a different approach by trying to eliminate the root cause of lupus rather than just managing its symptoms.
You likely qualify if…
You likely don't qualify if…
If enrolled, you will undergo a procedure to collect your own immune cells from your blood. These cells will be sent to a laboratory where they are genetically modified and grown for a very short time (about 10 minutes of preparation). You will then receive the modified cells back through an infusion. The trial will monitor you closely with blood tests and clinical visits to assess whether the treatment is safe and whether your lupus improves over time.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
The Children's Hospital of Zhejiang University School of Medicine
Enrollment target
~18 participants
Started
November 2025
Primary completion
May 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
5 Years and older
Last updated on clinicaltrials.gov in November 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jianhua Mao, MD
The Children's Hospital of Zhejiang University School of Medicine
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.